Trial Profile
A Phase II, Randomized Clinical Trial to Study the Safety, Tolerability, and Efficacy of the Combination Regimen of MK-5172 and MK-8742 in Japanese Subjects With Chronic Hepatitis C and a Phase III, Randomized Placebo-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of the Combination Regimen of MK-5172 and MK-8742 in Japanese Subjects With Chronic Hepatitis C
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Elbasvir (Primary) ; Elbasvir/grazoprevir (Primary) ; Grazoprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 19 Feb 2019 Results of integrated analysis of data from 12 international phase 2/3 clinical trials(NCT01717326,NCT01932762,NCT02092350,NCT02105467,NCT02105662,NCT02105688,NCT02105701,NCT02115321,NCT02203149,NCT02251990,NCT02252016 and NCT02358044) assessing safety and efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis C Virus Genotypes 1 and 4 Infection published in the Journal of Gastroenterology and Hepatology
- 03 Oct 2016 According to a Merck & Co media release, data from phase III portion of the study will be presented at The Liver Meeting 2016.
- 19 May 2016 Status changed from active, no longer recruiting to completed.